Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic

Meir Medical Center225 enrolled

Overview

During the second week of September( week 38 of the year)there are recorded data of exacerbation of asthma all over the world, including Israel. A short preventive treatment of 6 weeks may reduce asthma exacerbation in children,reduce primary care and ER visiting and hospitalization. We will study the effectiveness of Budicort or Symbicort turbuhaler as a preventive treatment in children aged 6-18 years.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

225

Conditions

Asthma Exacerbation

Interventions

Budesonide turbuhaler, Budesonide+Formoterol turbuhalerDRUG

Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: age : 6-18 years suffering from asthma asthma exacerbation during 1/9/2009-15/10/2009 \- Exclusion Criteria: any chronic condition that can involve respiratory tract (other than asthma) treated as prevention with ICS or montelukast from July 2010 Treated with oral steroids during the August 2010 asthma exacerbation one week prior study inclusion

Locations (1)

Meir Medical Center

Kfar Saba, Israel

RECRUITING

Outcomes

Primary Outcomes

reduction of asthma exacerbation during the study period

less asthma exacerbation

Time frame: An average time of 8 weeks

Secondary Outcomes

less primary care physician visits

less primary care physician visits less ER visits less hospitalization due to asthma exacerbation

Time frame: An average time of 8 weeks

Central Contacts

Avner He Cohen, MD

CONTACT

972-3-9398200 hermanc@post.tau.ac.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.